Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Mini Rev Med Chem. 2024;24(6):601-617. doi: 10.2174/1389557523666230825144150.
Although there have been significant advancements in cancer treatment, resistance and recurrence in patients make it one of the leading causes of death worldwide. 5-fluorouracil (5-FU), an antimetabolite agent, is widely used in treating a broad range of human malignancies. The cytotoxic effects of 5-FU are mediated by the inhibition of thymidylate synthase (TYMS/TS), resulting in the suppression of essential biosynthetic activity, as well as the misincorporation of its metabolites into RNA and DNA. Despite its huge benefits in cancer therapy, the application of 5-FU in the clinic is restricted due to the occurrence of drug resistance. MicroRNAs (miRNAs) are small, non-coding RNAs that act as negative regulators in many gene expression processes. Research has shown that changes in miRNA play a role in cancer progression and drug resistance. This review examines the role of miRNAs in 5-FU drug resistance in cancers.
尽管癌症治疗取得了重大进展，但患者的耐药性和复发仍然是全球主要的死亡原因之一。氟尿嘧啶（5-FU）是一种抗代谢药物，广泛用于治疗多种人类恶性肿瘤。5-FU 的细胞毒性作用是通过抑制胸苷酸合成酶（TYMS/TS）介导的，从而抑制必需的生物合成活性，以及其代谢物错误掺入 RNA 和 DNA。尽管 5-FU 在癌症治疗中有巨大的益处，但由于耐药性的发生，其在临床上的应用受到限制。microRNAs（miRNAs）是一种小的非编码 RNA，在许多基因表达过程中充当负调控因子。研究表明，miRNA 的变化在癌症的进展和耐药性中起作用。本综述探讨了 miRNAs 在癌症中 5-FU 耐药性中的作用。
Zotero 插件